|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marumoto T and Saya H: Molecular biology
of glioma. Adv Exp Med Biol. 746:2–11. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ma Z: Downregulation of SETD8 by miR-382
is involved in glioma progression. Pathol Res Pract. 214:356–360.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tan Z, Zhao J and Jiang Y: miR-634
sensitizes glioma cells to temozolomide by targeting CYR61 through
Raf-ERK signaling pathway. Cancer Med. 7:913–921. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu L, Liu Z, Wang H, Chen L, Ruan F,
Zhang J, Hu Y, Luo H and Wen S: 14-3-3β exerts glioma-promoting
effects and is associated with malignant progression and poor
prognosis in patients with glioma. Exp Ther Med. 15:2381–2387.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Peng Z, Liu C and Wu M: New insights into
long noncoding RNAs and their roles in glioma. Mol Cancer.
17(61)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L,
Li X, Sun L and Gong Z: SCD1 confers temozolomide resistance to
human glioma cells via the Akt/GSK3β/β-catenin signaling axis.
Front Pharmacol. 8(960)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Che F, Xie X, Wang L, Su Q, Jia F, Ye Y,
Zang L, Wang J, Li H, Quan Y, et al: B7-H6 expression is induced by
lipopolysaccharide and facilitates cancer invasion and metastasis
in human gliomas. Int Immunopharmacol. 59:318–327. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang HD, Jiang LH, Sun DW, Li J and Ji
ZL: The role of miR-130a in cancer. Breast Cancer. 24:521–527.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Song H, Zhang Y, Liu N, Wan C, Zhang D,
Zhao S, Kong Y and Yuan L: miR-92b regulates glioma cells
proliferation, migration, invasion, and apoptosis via PTEN/Akt
signaling pathway. J Physiol Biochem. 72:201–211. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stojcheva N, Schechtmann G, Sass S, Roth
P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis
FJ, et al: MicroRNA-138 promotes acquired alkylator resistance in
glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Oncotarget. 7:12937–12950. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu Y, Zhao H, Rao M and Xu S:
MicroRNA-365 inhibits proliferation, migration and invasion of
glioma by targeting PIK3R3. Oncol Rep. 37:2185–2192.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang T, Ma G, Zhang Y, Huo H and Zhao Y:
miR-599 inhibits proliferation and invasion of glioma by targeting
periostin. Biotechnol Lett. 39:1325–1333. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li Y, Tan W, Neo TW, Aung MO, Wasser S,
Lim SG and Tan TM: Role of the miR-106b-25 microRNA cluster in
hepatocellular carcinoma. Cancer Sci. 100:1234–1242.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ding X, Zhong T, Jiang L, Huang J, Xia Y
and Hu R: miR-25 enhances cell migration and invasion in
non-small-cell lung cancer cells via ERK signaling pathway by
inhibiting KLF4. Mol Med Rep. 17:7005–7016. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
He J, Qi H, Chen F and Cao C: MicroRNA-25
contributes to cisplatin resistance in gastric cancer cells by
inhibiting forkhead box O3a. Oncol Lett. 14:6097–6102.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Peng G, Yuan X, Yuan J, Liu Q, Dai M, Shen
C, Ma J, Liao Y and Jiang W: miR-25 promotes glioblastoma cell
proliferation and invasion by directly targeting NEFL. Mol Cell
Biochem. 409:103–111. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang J, Gong X, Tian K, Chen D, Sun J,
Wang G and Guo M: miR-25 promotes glioma cell proliferation by
targeting CDKN1C. Biomed Pharmacother. 71:7–14. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xiang J, Hang JB, Che JM and Li HC: MiR-25
is up-regulated in non-small cell lung cancer and promotes cell
proliferation and motility by targeting FBXW7. Int J Clin Exp
Pathol. 8:9147–9153. 2015.PubMed/NCBI
|
|
25
|
Feng S, Pan W, Jin Y and Zheng J: MiR-25
promotes ovarian cancer proliferation and motility by targeting
LATS2. Tumour Biol. 35:12339–12344. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhao H, Wang Y, Yang L, Jiang R and Li W:
MiR-25 promotes gastric cancer cells growth and motility by
targeting RECK. Mol Cell Biochem. 385:207–213. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen H, Pan H, Qian Y, Zhou W and Liu X:
MiR-25-3p promotes the proliferation of triple negative breast
cancer by targeting BTG2. Mol Cancer. 17(4)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wu MZ, Cheng WC, Chen SF, Nieh S, O'Connor
C, Liu CL, Tsai WW, Wu CJ, Martin L, Lin YS, et al: miR-25/93
mediates hypoxia-induced immunosuppression by repressing cGAS. Nat
Cell Biol. 19:1286–1296. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Chen B, Liu J, Qu J, Song Y, Li Y and Pan
S: MicroRNA-25 suppresses proliferation, migration, and invasion of
osteosarcoma by targeting SOX4. Tumour Biol.
39(1010428317703841)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
He W, Li X, Xu S, Ai J, Gong Y, Gregg JL,
Guan R, Qiu W, Xin D, Gingrich JR, et al: Aberrant methylation and
loss of CADM2 tumor suppressor expression is associated with human
renal cell carcinoma tumor progression. Biochem Biophys Res Commun.
435:526–532. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang S, Yan HL, Tao QF, Yuan SX, Tang GN,
Yang Y, Wang LL, Zhang YL, Sun SH and Zhou WP: Low CADM2 expression
predicts high recurrence risk of hepatocellular carcinoma patients
after hepatectomy. J Cancer Res Clin Oncol. 140:109–116.
2014.PubMed/NCBI View Article : Google Scholar
|
